Deucravacitinib for Hair Loss

This trial aims to test a new treatment, deucravacitinib, for two types of hair loss: Central Centrifugal Cicatricial Alopecia (CCCA) and Frontal Fibrosing Alopecia (FFA). Participants will take deucravacitinib daily for 48 weeks to evaluate its effectiveness in promoting hair regrowth and reducing symptoms. The trial seeks individuals who have experienced moderate-to-severe hair loss from CCCA or FFA for at least 6 months and are generally in good health. Researchers will monitor participants at the Icahn School of Medicine at Mount Sinai to ensure safety and effectiveness. As a Phase 2 trial, the research focuses on assessing the treatment's efficacy in an initial, smaller group of people.

Yes, you may need to stop certain medications before joining the trial. Specifically, you cannot use systemic immunosuppressive medications, certain non-biologic systemic agents, intralesional corticosteroids, oral JAK inhibitors, or topical corticosteroids close to the start of the trial. There are specific timeframes for stopping these medications, such as 8 weeks for some and 4 weeks for others before the baseline visit.

Studies have shown that deucravacitinib is generally well-tolerated by patients. Real-world research indicates that most people handle the treatment well, though some new risks have been identified. Common side effects include mild issues like headaches or stomach upset, but these do not affect everyone. No major safety concerns would prevent most people from trying the treatment safely. However, as with any medication, monitoring for unexpected reactions is important.¹²³⁴⁵

Deucravacitinib is unique because it targets the JAK-STAT signaling pathway, which is not the focus of most current treatments for hair loss conditions like Frontal Fibrosing Alopecia and Central Centrifugal Cicatricial Alopecia. Existing treatments often rely on anti-inflammatory medications or topical steroids. However, Deucravacitinib, a selective TYK2 inhibitor, offers a more targeted approach by specifically modulating immune pathways involved in these conditions. Researchers are excited about this treatment due to its potential for greater effectiveness and fewer side effects compared to traditional options.

Research has shown that deucravacitinib, a treatment targeting a specific enzyme, might help manage conditions like Frontal Fibrosing Alopecia (FFA). In this trial, participants with FFA will receive deucravacitinib to evaluate its effectiveness. Patients with similar conditions have experienced significant symptom improvements with treatments that work similarly, such as JAK inhibitors. For Central Centrifugal Cicatricial Alopecia (CCCA), another group in this trial will receive deucravacitinib, although its effectiveness for CCCA remains unclear. Some studies did not achieve their goals for hair regrowth, suggesting it might not work well for CCCA. However, responses to treatments can vary among individuals.¹⁶⁷⁸⁹